MARKET

CYTK

CYTK

Cytokinetics Inc
NASDAQ
38.01
-0.57
-1.48%
After Hours: 38.16 +0.15 +0.39% 17:02 07/15 EDT
OPEN
38.73
PREV CLOSE
38.58
HIGH
38.89
LOW
37.59
VOLUME
1.75M
TURNOVER
--
52 WEEK HIGH
61.38
52 WEEK LOW
29.31
MARKET CAP
4.54B
P/E (TTM)
-7.1606
1D
5D
1M
3M
1Y
5Y
1D
Cytokinetics CEO Makes a Significant Stock Move!
TipRanks · 2h ago
Robert I. Blum, President & CEO, Reports Disposal of Common Shares in Cytokinetics Inc
Reuters · 7h ago
Weekly Report: what happened at CYTK last week (0707-0711)?
Weekly Report · 1d ago
Cytokinetics Insiders Sold US$9.5m Of Shares Suggesting Hesitancy
Simply Wall St · 3d ago
Cytokinetics Advances Pediatric Heart Treatment with Aficamten Study
TipRanks · 5d ago
CYTOKINETICS ANNOUNCES FIVE PRESENTATIONS RELATED TO AFICAMTEN AT THE EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2025
Reuters · 5d ago
Top Executive at Cytokinetics Makes Significant Stock Sale
TipRanks · 07/09 02:01
Fady Ibraham Malik, EVP of Research & Development, Reports Disposal of Cytokinetics Common Shares
Reuters · 07/08 20:22
More
About CYTK
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

Webull offers Cytokinetics, Inc. stock information, including NASDAQ: CYTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYTK stock methods without spending real money on the virtual paper trading platform.